Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy

Acral (AM) and mucosal melanomas (MM) are rare subtypes with a poor prognosis. In those with advanced disease, anti-PD-1 (PD1) therapy has reduced activity compared to that seen in non-acral cutaneous melanoma.

Source: European Journal of Cancer - January 22, 2024 Category: Cancer & Oncology Authors: Sarah K. Jacques, Janet McKeown, Piyush Grover, Douglas B. Johnson, Anne Zaremba, Florentia Dimitriou, Roi Weiser, Mohamad Farid, Kenjiro Namikawa, Ryan J. Sullivan, Piotr Rutkowski, Celeste Lebbe, Omid Hamid, Jonathan S. Zager, Olivier Michielin, Bart Ne Tags: Original Research Source Type: research